+47.9%
MS vs MRNA
+511.3%
-463.4%
-18.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.3% | -2.2% | +2.5% | +0.3% |
| 7D | +1.4% | +5.5% | -4.1% | +1.3% |
| 30D | -0.3% | +158.7% | -159.0% | -2.4% |
| 3M | +0.3% | +182.1% | -181.8% | -3.1% |
| 6M | +31.3% | +151.8% | -120.5% | +27.6% |
| YTD | +24.7% | +393.6% | -368.9% | +14.1% |
| 1Y | +47.9% | +499.5% | -451.6% | +34.7% |
| All | +47.9% | +511.3% | -463.4% | +34.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling